mutLBSgeneDB |
Gene summary for TRIM32 |
Gene summary |
Basic gene Info. | Gene symbol | TRIM32 |
Gene name | tripartite motif containing 32 | |
Synonyms | BBS11|HT2A|LGMD2H|TATIP | |
Cytomap | UCSC genome browser: 9q33.1 | |
Type of gene | protein-coding | |
RefGenes | NM_001099679.1, NM_012210.3, | |
Description | 72 kDa Tat-interacting proteinE3 ubiquitin-protein ligase TRIM32TAT-interactive protein, 72-KDtripartite motif-containing 32tripartite motif-containing protein 32zinc finger protein HT2Azinc-finger protein HT2A | |
Modification date | 20141219 | |
dbXrefs | MIM : 602290 | |
HGNC : HGNC | ||
Ensembl : ENSG00000119401 | ||
HPRD : 03797 | ||
Vega : OTTHUMG00000021026 | ||
Protein | UniProt: Q13049 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_TRIM32 | |
BioGPS: 22954 | ||
Pathway | NCI Pathway Interaction Database: TRIM32 | |
KEGG: TRIM32 | ||
REACTOME: TRIM32 | ||
Pathway Commons: TRIM32 | ||
Context | iHOP: TRIM32 | |
ligand binding site mutation search in PubMed: TRIM32 | ||
UCL Cancer Institute: TRIM32 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0000209 | protein polyubiquitination | 18632609 | GO:0016567 | protein ubiquitination | 16816390 | GO:0030307 | positive regulation of cell growth | 18632609 | GO:0030335 | positive regulation of cell migration | 18632609 | GO:0032897 | negative regulation of viral transcription | 18248090 | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 23077300 | GO:0045087 | innate immune response | 18248090 | GO:0045787 | positive regulation of cell cycle | 18632609 | GO:0045862 | positive regulation of proteolysis | 18632609 | GO:0051091 | positive regulation of sequence-specific DNA binding transcription factor activity | 23077300 | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 23077300 | GO:1902187 | negative regulation of viral release from host cell | 18248090 | GO:1902230 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 18632609 |
Top |
Ligand binding site mutations for TRIM32 |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | C20 | L18I | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for TRIM32 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | C20 | L18I | -0.72878122 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for TRIM32 from PDB |
Top |
Differential gene expression and gene-gene network for TRIM32 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for TRIM32 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0270968 | Limb-girdle muscular dystrophy type 2H | 9 | Biomarker, GeneticVariation |
umls:C0752166 | Bardet-Biedl Syndrome | 7 | Biomarker, GeneticVariation |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for TRIM32 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of TRIM32 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of TRIM32 |
Multiple alignments for Q13049 in multiple species |
LBS | AA sequence | # species | Species |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |